Calidi Biotherapeutics
CLDI
26 hedge funds and large institutions have $40.6M invested in Calidi Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
8% more funds holding
Funds holding: 24 → 26 (+2)
3% more capital invested
Capital invested by funds: $39.6M → $40.6M (+$1.08M)
0.01% more ownership
Funds ownership: 0.79% → 0.8% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$3.83M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.42M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$1.09M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$200K |
| 5 |
VF
Virtu Financial
New York
|
+$178K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
-$4.07M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$1.22M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$954K |
| 4 |
E
Ergoteles
New York
|
-$414K |
| 5 |
EC
Elequin Capital
New York
|
-$2.45K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
26
Clear Street
New York
| $11.2K | +$9.81K | +8 | +800% |
|
27
UBS Group
Zurich,
Switzerland
| $113 | – | – | – |
|
|
FTCM
28
First Trust Capital Management
Chicago,
Illinois
| – | -$4.07M | -3,333 | Closed |
|
|
29
Citadel Advisors
Miami,
Florida
| – | -$954K | -782 | Closed |
|
CLDI Hedge Fund Activity: Q1 2023 in Review
26 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q1 2023, worth a combined $40.6M — up 2.7% from $39.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CLDI positions and 2 closed out — a net gain of 2 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Glazer Capital LLC, opening a new position worth an estimated $3.83M. The largest seller was First Trust Capital Management, exiting entirely with an estimated $4.07M sold.
- 26 institutional investors held Calidi Biotherapeutics (CLDI) as of Q1 2023, up from 24 in Q4 2022.
- Funds reported $40.6M of Calidi Biotherapeutics stock for Q1 2023, up 2.7% quarter-over-quarter.
- 4 funds opened new Calidi Biotherapeutics positions in Q1 2023 and 2 closed out, a net change of +2 holders.
- The largest Calidi Biotherapeutics buyer in Q1 2023 was Glazer Capital LLC, an estimated $3.83M added.
- The largest Calidi Biotherapeutics seller in Q1 2023 was First Trust Capital Management, an estimated $4.07M sold.
Based on aggregated 13F filings for Q1 2023.